RE Royalties has invested $1.5 million to acquire a gross revenue royalty on a 14.2 MW portfolio of rooftop solar projects in the Philippines, expanding its international renewable energy portfolio and establishing a strategic partnership with Singapore Solar. The projects are operational with long-term commercial agreements, providing immediate cash flow. Additionally, RE Royalties announced full repayment of its $4.6 million secured loan for a renewable natural gas project in Wisconsin, with royalty payments now commencing. These moves strengthen RE Royalties' global portfolio and cash flow, supporting its strategy to grow long-term recurring revenue assets worldwide.
RE Royalties' recent $1.5 million royalty acquisition in the Philippines provides context for energy sector investors. For readers following the energy sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 79 priced US energy stocks, 35 rose and 43 fell. Notable movers include Transocean Ltd (RIG) at USD 5.92 with a 5.25% increase, Valaris Limited (VAL) at USD 89.65 up 5.08%, and Patterson-UTI Energy Inc. (PTEN) at USD 12.04 rising 4.74%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
